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Abstract 
Leuconostoc is a gram-positive coccus characterized by its resistance to glycopeptide 
antibiotics. Generally, this bacterium is susceptible to -lactam antibiotics; however, 
here we present a leukemia patient who developed leuconostoc bacteremia during 
antimicrobial therapy with carbapenem. The appropriate choice of antibiotics with 
optimal doses enables leuconostoc infection to be overcome even in compromised 
hosts. We report 3 cases of leuconostoc bacteremia, the leukemia case which was 
successfully treated, along with discussion of two other cases with malignancies. 
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Introduction 
Chemotherapy for patients with malignancies often causes critical infections because of 
the use of cytotoxic agents and the immunodeficiency associated with the disease itself. 
In particular, remission induction therapy for hematologic malignancies causes severe 
neutropenia for 2 weeks or even longer, which can lead to fatal infection. Antimicrobial 
therapy in such cases is clinically less effective, even with treatment following the IDSA 
guideline 1. 
Generally, microbial substitution develops from inappropriate use of antibiotics. 
Most bacteria in such cases have attenuated virulence, but patients with infections 
caused by such bacteria often have a dismal outcome because of their poor general 
conditions and bacterial resistance to antibiotics. 
Leuconostoc is a gram-positive coccus, that has multi-drug resistance; in 
particular, this bacterium is characterized by native resistance for glycopeptides such as 
vancomycin (VCM) because it lacks binding sites for these agents 2. Some reports have 
documented successful treatment of Leuconostoc bacteremia, but most of these are old 
3,4, and there are very few papers published in the ‘carbapenem era’ relating to this 
bacterium 5,6. We report here a case in which Leuconostoc bacteremia that developed 
during chemotherapy for leukemia was successfully treated, along with discussion of 
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two other cases. 
 
Case report 
Case 1. A 52-year-old woman was referred to our institution for hypermenorrhea and 
pancytopenia. The morphological examination of bone marrow smears showed 58% 
myeloblasts, resulting in a diagnosis of acute myeloid leukemia (AML). The patient was 
treated with remission induction chemotherapy for AML, consisting of idarubicin and 
cytarabine. Since febrile neutropenia developed after chemotherapy, cefepim (CFPM) 
was given, followed by a combination of meropenem (MEPM), teicoplanin, and 
micafungin (MCFG) 3 days after CFPM treatment, but moderate fever persisted. 
Leukocyte counts recovered slowly around 3 weeks after the initial chemotherapy, but 
the majority of leukocytes were myeloblasts, with no normal granulocytes in the 
peripheral blood (Figure). Therefore, second remission induction therapy consisting of 
daunomycin and cytarabine was performed while continuing antimicrobial therapy for 
persistent fever. The patient’s temperature normalized around the 7th day after the 
second chemotherapy regimen, while on biapenem (BIPM) and MCFG (Figure). 
However, moderate fever reappeared on day 12. A gram-positive coccus was detected in 
blood culture samples obtained the same day, and vancomycin (VCM) was added the 
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next day. On the 14th day, the patient developed cellulitis involving the right thigh, and 
the blood culture revealed that the gram-positive coccus was a Leuconostoc species. 
According to the drug susceptibility test (Table 1a), the antibiotics were switched to 
imipenem/cilastatin (IPM/CS), gentamicin (GM), and MCFG. Clindamycin (CLDM) 
was added from day 16 because her fever pattern was worsening. On day 17, the blood 
culture taken on day 13 was found to be positive for Leuconostoc and 
Stenotrophomonas maltophilia (results of the drug susceptibility were shown in Table 
1b); GM was deemed ineffective and was discontinued, and 
sulfamethoxazole-trimethoprim was started. Her fever then improved, and she was 
afebrile on day 27, when she achieved remission of leukemia, and her neutrophils 
exceeded 500/l. The result of the minimal inhibitory concentration (MIC) tests for the 
bacteria, obtained at a later date, revealed that the Leuconostoc was susceptible to 
IPM/CS at less than 1 g/ml and BIPM at less than 4 g/ml, although the patient was 
being treated with carbapenem when the bacterial infection developed. 
  
Case 2. A 73-year-old man presented with high fever and brown urine. On physical 
examination, he had jaundice of his bulbar conjunctiva and hepatosplenomegaly. On 
admission, he presented with pancytopenia, high C-reactive protein levels, and hepatic 
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dysfunction. Computed tomography showed multiple neck lymphadenopathy in his 
neck and hepatosplenomegaly. Atypical lymphocytes were increased on bone marrow 
smears, leading to the diagnosis of non-Hodgkin’s lymphoma. The patient was treated 
with CHOP therapy, consisting of cyclophosphamide, doxorubicin hydrochloride, 
vincristine, and prednisolone. However, the effect of the chemotherapy was transient; 
persistent fever and hepatosplenomegaly improved after the first dose of CHOP, but 
these symptoms flared up around 15 days after the therapy. There were no symptoms 
suggesting focal infection, which led to the diagnosis of tumor fever. However, the 
patient was given 1.5 g/day of MEPM and fluconazole (FLCZ) when the second course 
of CHOP therapy was started on the 18th day, because he was an immunocompromised 
host with no granulocytes. Since his fever and hepatosplenomegaly improved 
immediately, the antibiotics were stopped on day 6 after the 2nd CHOP therapy. 
Because a high fever reappeared on day 10, the antimicrobial and antifungal therapies 
(panipenem/betamipron at 2 g/day, GM, and FLCZ) were restarted. Since the blood 
culture was positive for -Streptococcus on day 10, these drugs were continued based 
on the drug susceptibility test results (Table 1a). VCM was added on day 14 for high 
fever, but the patient developed acute respiratory distress syndrome (ARDS) and died 
on day 15. On autopsy, the patient had systemic lymphadenopathy, hepatosplenomegaly 
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with nodular lesions consisting of T-cell lineage non-Hodgkin’s lymphoma, and severe 
pulmonary edema. Involvement of Leuconostoc species in the development of ARDS 
was unclear, and intracardiac blood culture was not performed. Since the attending 
physician noticed the contradictory result for the susceptibility test for -Streptococcus 
indicating resistance to VCM, the blood culture test was re-evaluated, and the 
gram-positive coccus was found to be a Leuconostoc species. 
 
Case 3. A 65-year old man, who was being seen regularly at a clinic for alcoholic liver 
cirrhosis, was referred to our institution for investigation of a space occupying lesion 
(SOL) of the liver. The SOL was diagnosed as hepatocellular carcinoma by angiography 
and magnetic resonance imaging, but the patient was not a candidate for aggressive 
treatment because of hepatic failure. Low-grade fever developed during the admission, 
and he was treated with piperacillin (PIPC) for 10 days. Since there were no signs of 
focal infection, the major reason for the fever was considered to be the patient’s 
compromised status due to end-stage hepatic failure. His antibiotics were switched to 
IPM/CS, 1 g/day, because a moderate fever developed on the 11th day after PIPC 
administration, and the temperature decreased came down. On the 8th day after 
withdrawal of IPM/CS, the moderate fever reappeared, and 1 g/day of IPM/CS was 
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restarted. Since coagulase-negative Staphylococcus (CNS) and Clostridium species were 
detected in the blood culture samples taken on the day when the fever flared up, the 
central venous catheter was removed. The fever disappeared temporarily, and the blood 
culture became negative for CNS. However, a high fever developed on the 9th day after 
the restart of IPM/CS. -Streptococcus, susceptible to IPM/CS on susceptibility testing 
(Table 1a), was detected in the blood culture sample collected on the same day when the 
fever flared up. However, the patient’s blood pressure decreased, and the patient died on 
the 5th day after the IPM/CS was restarted. The blood culture test was re-evaluated 
because resistance of the bacterium to VCM was incidentally discovered as a result of 




Leuconostoc is a nonpathogenic resident of the intestinal tract and is detected in 
immunocompromised hosts, such as organ transplant recipients and patients with 
malignancy receiving intensive chemotherapy. The primary characteristic of this 
bacterium is its resistance to glycopeptides and the poor clinical effectiveness of 
-lactam antibiotics, even though drug susceptibility testing shows that it is 
K. Ishiyama et al. 
Leuconostoc bacteremia in 3 patients with malignancies. 
 9 / 15 
 
‘susceptible’ to -lactam antibiotics, as the MIC is relatively high. In our experience, 
shown in Table 1, the MIC was as poor as previously reported 6. The recommended 
treatment for Leuconostoc species is penicillin, ampicillin, CLDM, minocycline, 
erythromycin, tobramycin, or GM 7. The results of susceptibility testing may vary; as 
indicated in Table 1a, poor susceptibility against penicillin G and ampicillin was 
observed in case 2. The laboratory data must be carefully followed when such difficult 
cases are encountered. Daptomycin, a novel lipopeptide antibiotic showing a good MIC 
for Leuconostoc but which is not authorized in Japan, must be considered a first-line 
drug for the treatment of Leuconostoc infection 8. 
Cases of Leuconostoc bacteremia, for which the MIC for carbapenem 
antibiotics has been previously reported, are listed in Table 2. Cancers, burn injuries, 
and short bowel syndrome in pediatric patients are common underlying diseases. 
Important risk factors for the development of Leuconostoc bacteremia include invasive 
mechanical ventilation and complications such as antecedent infection or surgery. All 
but one patient developed Leuconostoc bacteremia during antimicrobial therapy, 
suggesting that the bacteria is replaced as microbial substitution. The range of MIC for 
carbapenem varied from 0.01 g/ml to 8.00 g/ml, indicating that the attending 
physician should choose antibiotics based on the results of antimicrobial susceptibility 
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testing. 
The common characteristics of our three cases were their immunocompromised 
status and the development of Leuconostoc infection during carbapenem use (or it was 
stopped just before in case 2). With the increase in the number of cancer patients, the 
opportunity to choose carbapenem antibiotics following the IDSA guideline has 
increased. Most Leuconostoc species should be susceptible to carbapenem antibiotics, 
but some Leuconostoc strains are resistant or have a relatively high MIC (Table 2) to the 
agent 5,9. Moreover, our experience supports the previous reports that the MIC level 
against Leuconostoc might differ slightly for carbapenems. Furthermore, it is important 
to note that two of the three cases were initially misdiagnosed as -Streptococcus. The 
major reason for the error could be the rarity of Leuconostoc 4,10; clinical laboratory 
technicians might miss it even when the results of microbial sensitivity testing are 
incompatible for -Streptococcus. Provision of detailed clinical information from the 
bedside to the laboratory could avoid such errors. 
Leuconostoc has attenuated virulence, but it appears to be a critical pathogen in 
immunocompromised patients. Generally, Leuconostoc have a susceptibility to the 
carbapenem antibiotics, however, the effect of the antibiotics are sometimes insufficient 
as in the present cases. Avoiding inappropriate use of broad-spectrum antibiotics, such 
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as carbapenem, might lead to prevention of Leuconostoc infection. When Leuconostoc 
infection occurs, appropriate choice of antibiotics with optimal doses using in 
combination and with careful observation can result in successful treatment even in 
compromised hosts. Collecting and analyzing information, such as the fever pattern, the 
results of repeated blood culture tests, susceptibility testing of the detected bacteria, and 
close liaison between laboratory and bedside are needed. 
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Figure legend 
Figure. Clinical course of case 1. Arrow shows the collection of blood cultures. *: 
Positive for leuconostoc, +: positive for Stenotrophomonas maltophilia in the blood 
culture samples.  
Abbreviations: BIPM, biapenem; CLDM, clindamycin; IPM/CS, imipenem/cilastatin; 
MEPM, melopenem; MCFG, micafungin; S-T, sulfamethoxazole-trimethoprim; VCM, 
vancomycin. 
 
Table 2. Clinical and microbiological characteristics of patients reported with Leuconostoc bacteremia, including MIC to carbapenem.
Age Sex Underlying disease Complications Microbiological diagnosis Prior therapy MIC (g/ml)
to carbapenem
Treatment Outcome Reference





MRSE bacteremia Leuconostoc citreum VCM IPM; 0.01 ABPC, catheter removal improved 4
34 years F AML (HSCT), graft-versus-host disease Leuconostoc sp. TEIC IPM; 8.00 ABPC, GM improved 6
68 years M Esophageal cancer none Leuconostoc mesenteroides FMOX, TOB IPM; 4.00 IPM/CS dead (10 days) 11
63 years M Pancreatic cancer Acute obstructive suppurativecholangitis Leuconostoc lactis LMOX IPM; 2.00 LMOX, -globulin, drainage improved 11
1 year F Short bowel syndrome Central venous catheter infection(MRSE) Leuconostoc sp. CAZ, VCM IPM; 1.00 ABPC, catheter removal improved 12
31 years M Burn injury none Leuconostoc cremoris IPM/CS, AMK IPM; S* ABPC, catheter removal improved 13
52 years M Liver abscess none Leuconostoc lactis CPFX, NTL,metronidazole IPM; S* IPM/CS, NTL, drainage improved 14
55 years M Polytrauma (Artificial ventilation) Leuconostoc lactis NA IPM; 1.50 PIPC/TAZ, CPFX unknown (transferred) 15
25 years F NHL (Chemotherapy), febrile Leuconostoc pseudomesenteroides NA IPM; 1.00 AMPC/CVA, GM, CPFX, ABPCunknown (discharged) 15
4 years M Bronchopneumonia none Leuconostoc mesenteroides ssp.Mesenteroides NA IPM; 4.00 AMK, CXM improved 15
49 years M Burn injury (Artificial ventilation) Leuconostoc mesenteroides ssp.Mesenteroides NA IPM; 6.00 CPFX, MEPM, ABPC, CL unknown (discharged) 15
18 years M Burn injury Tracheotomy, nephrectomy(artificial ventilation) Leuconostoc citreum NA IPM; 0.75 ABPC/SBT unknown (transferred) 15
6 months F Short bowel syndrome Ileus Leuconostoc lactis NA IPM; 1.50 AMPC/CVA unknown (discharged) 15




Leuconostoc sp. CTX, VCM MEPM; 3.00 ABPC, GM, catheter removal improved 16
Present report
52 years M AML (Chemotherapy), febrile neutropeniaLeuconostoc sp. CFPM,MEPM,
IPM; 1.00,
BIPM; 4.00 IPM/CS, GM, VCM, CLDM, STimproved Case 1
73 years M NHL (Chemotherapy), febrile neutropeniaLeuconostoc sp. MEPM, FLCZ IPM; S PAPM/BP, GM, VCM, FLCZ dead (5 days) Case 2
65 years M Hepatic failure none Leuconostoc sp. PIPC, IPM/CS IPM; S IPM/CS, catheter removal dead (5 days) Case 3
*: Described only the results of drug susceptibility testing.
Abbreviations: ABPC; ampicillin, AMI; acute myocardial infarction, AMK; amikacin, AML; acute myeloid leukemia, AMPC; amoxicillin, BIPM; biapenem, CL; colistin, CLDM; clindamycin, CPFX; ciprofloxacin, CS;
cilastatin, CTX; cefotaxime, CTZ; ceftezole, CVA; clavulanic acid, CXM; cefuroxime, ELBWI; extremely low birth weight infant, FLCZ; fluconazole, FMOX; flomoxef, GM; gentamicin, HSCT; hematopoietic stem
cell transplantation, IPM; imipenem, LMOX; latamoxef, MCFG; micafungin, MEPM; meropenem, MIC; minimum inhibitory concentration, MRSE; methicillin-resistant Staphylococcus epidermidis , NA; information


















































Figure. Clinical course of case 1.
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